PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1993 January; 67(1): 15–23.
PMCID: PMC1968214

Humoral mediation for cachexia in tumour-bearing rats.

Abstract

Early and severe loss of body weight associated with pronounced tissue changes developed in rats transplanted with a fast-growing ascites hepatoma (Yoshida AH-130). The protein content showed an early and marked fall in the skeletal muscle, while in the liver it transiently increased 4 days after implantation then declined to values lower than in control animals. Protein loss in gastrocnemius muscle and liver resulted mainly from enhancement of protein catabolism (Tessitore L. et al., Biochem. J., 241: 153-158, 1987). In contrast to the tumour-bearing rats, in the pair-fed animals the initial body weight was maintained, while the protein mass decreased sharply in the liver and moderately in the gastrocnemius muscle. In host animals total plasma protein decreased during the period of tumour growth, while both triglycerides and total cholesterol markedly increased. Glucose remained unchanged even when overt cachexia had developed. The total free amino acid concentration in the plasma of tumour-bearing rats decreased slightly by day 4 and returned to values close to those of controls in the late stages of tumour growth. By contrast, in the pair-fed controls the plasma levels of triglycerides and particularly of total free amino acids and glucose decreased over the whole experimental period, whereas total protein and cholesterol were unchanged. Marked perturbations in the hormonal homeostasis developed early after tumour transplantation. The plasma levels of glucagon, corticosterone and catecholamines rose sharply, while those of insulin and thyroid hormones decreased. Furthermore, high plasma concentrations of prostaglandin E2 (PGE2) and tumour necrosis factor (TNF) were observed over the whole experimental period. IL-1-like activity, TNF and PGE2 were released in vitro from AH-130 cells. These data suggest that the systemic effects of AH-130 tumour on the host rat reflected the interplay of a complex network of factors, including classical hormones and cytokines, all of which likely concur in enhancing tissue protein catabolism.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aderka D, Fisher S, Levo Y, Holtmann H, Hahn T, Wallach D. Cachectin/tumour-necrosis-factor production by cancer patients. Lancet. 1985 Nov 23;2(8465):1190–1190. [PubMed]
  • Aderka D, Englemann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991 Oct 15;51(20):5602–5607. [PubMed]
  • Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992 Feb 1;175(2):323–329. [PMC free article] [PubMed]
  • Aguilar-Santelises M, Magnusson R, Svenson SB, Loftenius A, Andersson B, Mellstedt H, Jondal M. Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression. Clin Exp Immunol. 1991 Jun;84(3):422–428. [PubMed]
  • Angeli A, Bisbocci D, Melo F, Frairia R, Gaidano GP. Relative competition of corticosterone, cortisol, cortisone, 11-dexycortisol and prednisolone with (1,2-3H)-cortisol in various protein-binding radioassay systems. Clin Chim Acta. 1975 Jun 20;61(3):279–286. [PubMed]
  • Argilés JM, López-Soriano FJ, Wiggins D, Williamson DH. Comparative effects of tumour necrosis factor-alpha (cachectin), interleukin-1-beta and tumour growth on amino acid metabolism in the rat in vivo. Absorption and tissue uptake of alpha-amino[1-14C]isobutyrate. Biochem J. 1989 Jul 15;261(2):357–362. [PubMed]
  • Arnal M, Obled C, Attaix D, Patureau-Mirand P, Bonin D. Dietary control of protein turnover. Diabete Metab. 1987 Nov-Dec;13(6):630–642. [PubMed]
  • Baccino FM, Tessitore L, Cecchini G, Messina M, Zuretti MF, Bonelli G, Gabriel L, Amenta JS. Control of cell protein catabolism in rat liver. Effects of starvation and administration of cycloheximide. Biochem J. 1982 Aug 15;206(2):395–405. [PubMed]
  • Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, Tavernier J, Fiers W. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet. 1987 Nov 28;2(8570):1229–1232. [PubMed]
  • Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med. 1983 Mar 10;308(10):553–558. [PubMed]
  • Beck SA, Tisdale MJ. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res. 1987 Nov 15;47(22):5919–5923. [PubMed]
  • Beck SA, Tisdale MJ. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Res. 1989 Jul 15;49(14):3800–3804. [PubMed]
  • Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 1991 Nov 15;51(22):6089–6093. [PubMed]
  • Beutler B, Cerami A. The history, properties, and biological effects of cachectin. Biochemistry. 1988 Oct 4;27(20):7575–7582. [PubMed]
  • Bozzetti F, Ammatuna M, Migliavacca S, Bonalumi MG, Facchetti G, Pupa A, Terno G. Total parenteral nutrition prevents further nutritional deterioration in patients with cancer cachexia. Ann Surg. 1987 Feb;205(2):138–143. [PubMed]
  • Candela M, Barker SC, Ballou LR. Sphingosine synergistically stimulates tumor necrosis factor alpha-induced prostaglandin E2 production in human fibroblasts. J Exp Med. 1991 Dec 1;174(6):1363–1369. [PMC free article] [PubMed]
  • Cannon JG, Dinarello CA. Increased plasma interleukin-1 activity in women after ovulation. Science. 1985 Mar 8;227(4691):1247–1249. [PubMed]
  • Darling G, Fraker DL, Jensen JC, Gorschboth CM, Norton JA. Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res. 1990 Jul 1;50(13):4008–4013. [PubMed]
  • Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985 Dec 1;162(6):2163–2168. [PMC free article] [PubMed]
  • del Rey A, Besedovsky H. Interleukin 1 affects glucose homeostasis. Am J Physiol. 1987 Nov;253(5 Pt 2):R794–R798. [PubMed]
  • Dessí S, Batetta B, Anchisi C, Pani P, Costelli P, Tessitore L, Baccino FM. Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). Br J Cancer. 1992 Nov;66(5):787–793. [PMC free article] [PubMed]
  • Evans RD, Argilés JM, Williamson DH. Metabolic effects of tumour necrosis factor-alpha (cachectin) and interleukin-1. Clin Sci (Lond) 1989 Oct;77(4):357–364. [PubMed]
  • Fearon KC, Hansell DT, Preston T, Plumb JA, Davies J, Shapiro D, Shenkin A, Calman KC, Burns HJ. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res. 1988 May 1;48(9):2590–2595. [PubMed]
  • Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest. 1987 Jul;80(1):184–190. [PMC free article] [PubMed]
  • Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984 Mar 30;68(1-2):167–175. [PubMed]
  • Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, Tracey KJ, Kuo G, Fischman DA, Cerami A, et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol. 1989 Mar;256(3 Pt 2):R659–R665. [PubMed]
  • Gatanaga T, Hwang CD, Kohr W, Cappuccini F, Lucci JA, 3rd, Jeffes EW, Lentz R, Tomich J, Yamamoto RS, Granger GA. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8781–8784. [PubMed]
  • Gelin J, Moldawer LL, Lönnroth C, Sherry B, Chizzonite R, Lundholm K. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 1991 Jan 1;51(1):415–421. [PubMed]
  • Goldberg AL. Protein turnover in skeletal muscle. II. Effects of denervation and cortisone on protein catabolism in skeletal muscle. J Biol Chem. 1969 Jun 25;244(12):3223–3229. [PubMed]
  • Goldings EA. Regulation of B cell tolerance by macrophage-derived mediators: antagonistic effects of prostaglandin E2 and interleukin 1. J Immunol. 1986 Feb 1;136(3):817–822. [PubMed]
  • Goodlad GA, Mitchell AJ, McPhail L, Clark CM. Serum insulin and somatomedin levels in the tumour-bearing rat. Eur J Cancer. 1975 Oct;11(10):733–737. [PubMed]
  • Grunfeld C, Wilking H, Neese R, Gavin LA, Moser AH, Gulli R, Serio MK, Feingold KR. Persistence of the hypertriglyceridemic effect of tumor necrosis factor despite development of tachyphylaxis to its anorectic/cachectic effects in rats. Cancer Res. 1989 May 15;49(10):2554–2560. [PubMed]
  • Jättelä M. Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest. 1991 Jun;64(6):724–742. [PubMed]
  • Kern KA, Norton JA. Cancer cachexia. JPEN J Parenter Enteral Nutr. 1988 May-Jun;12(3):286–298. [PubMed]
  • Kehrer P, Turnill D, Dayer JM, Muller AF, Gaillard RC. Human recombinant interleukin-1 beta and -alpha, but not recombinant tumor necrosis factor alpha stimulate ACTH release from rat anterior pituitary cells in vitro in a prostaglandin E2 and cAMP independent manner. Neuroendocrinology. 1988 Aug;48(2):160–166. [PubMed]
  • Kettelhut IC, Goldberg AL. Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue. J Clin Invest. 1988 May;81(5):1384–1389. [PMC free article] [PubMed]
  • KIBLER RF, TAYLOR WJ, MYERS JD. THE EFFECT OF GLUCAGON ON NET SPANCHNIC BALANCES OF GLUCOSE, AMINO ACID NITROGEN, UREA, KETONES, ANS OXYGEN IN MAN. J Clin Invest. 1964 May;43:904–915. [PMC free article] [PubMed]
  • Kien CL, Camitta BM. Increased whole-body protein turnover in sick children with newly diagnosed leukemia or lymphoma. Cancer Res. 1983 Nov;43(11):5586–5592. [PubMed]
  • Kien CL, Camitta BM. Close association of accelerated rates of whole body protein turnover (synthesis and breakdown) and energy expenditure in children with newly diagnosed acute lymphocytic leukemia. JPEN J Parenter Enteral Nutr. 1987 Mar-Apr;11(2):129–134. [PubMed]
  • Kumara-Siri MH, Lee K, Surks MI. Regulation of thyrotropin secretion in rats bearing the Walker 256 carcinoma. Endocrinology. 1981 Nov;109(5):1760–1768. [PubMed]
  • Lagopoulos L, Sunahara GI, Würzner H, Fliesen T, Stalder R. The correlation of body growth with diethylnitrosamine-induced hepatocarcinogenesis in relation to serum insulin and somatomedin-C. Carcinogenesis. 1991 Feb;12(2):211–215. [PubMed]
  • Lawson DH, Richmond A, Nixon DW, Rudman D. Metabolic approaches to cancer cachexia. Annu Rev Nutr. 1982;2:277–301. [PubMed]
  • Mahony SM, Tisdale MJ. Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor. Br J Cancer. 1988 Sep;58(3):345–349. [PMC free article] [PubMed]
  • Mealy K, van Lanschot JJ, Robinson BG, Rounds J, Wilmore DW. Are the catabolic effects of tumor necrosis factor mediated by glucocorticoids? Arch Surg. 1990 Jan;125(1):42–48. [PubMed]
  • Melville S, McNurlan MA, Calder AG, Garlick PJ. Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. Cancer Res. 1990 Feb 15;50(4):1125–1131. [PubMed]
  • Michie HR, Sherman ML, Spriggs DR, Rounds J, Christie M, Wilmore DW. Chronic TNF infusion causes anorexia but not accelerated nitrogen loss. Ann Surg. 1989 Jan;209(1):19–24. [PubMed]
  • Moldawer LL, Drott C, Lundholm K. Monocytic production and plasma bioactivities of interleukin-1 and tumour necrosis factor in human cancer. Eur J Clin Invest. 1988 Oct;18(5):486–492. [PubMed]
  • MOORE S, STEIN WH. Chromatography of amino acids on sulfonated polystyrene resins. J Biol Chem. 1951 Oct;192(2):663–681. [PubMed]
  • Morrison SD, Moley JF, Norton JA. Contribution of inert mass to experimental cancer cachexia in rats. J Natl Cancer Inst. 1984 Oct;73(4):991–998. [PubMed]
  • Morrison WL, Gibson JN, Jung RT, Rennie MJ. Skeletal muscle and whole body protein turnover in thyroid disease. Eur J Clin Invest. 1988 Feb;18(1):62–68. [PubMed]
  • Mulligan HD, Tisdale MJ. Lipogenesis in tumour and host tissues in mice bearing colonic adenocarcinomas. Br J Cancer. 1991 May;63(5):719–722. [PMC free article] [PubMed]
  • Nigam S, Becker R, Rosendahl U, Hammerstein J, Benedetto C, Barbero M, Slater TF. The concentrations of 6-keto-PGF1 alpha and TXB2 in plasma samples from patients with benign and malignant tumours of the breast. Prostaglandins. 1985 Apr;29(4):513–528. [PubMed]
  • Odedra BR, Millward DJ. Effect of corticosterone treatment on muscle protein turnover in adrenalectomized rats and diabetic rats maintained on insulin. Biochem J. 1982 Jun 15;204(3):663–672. [PubMed]
  • O'Keefe SJ, Ogden J, Ramjee G, Rund J. Contribution of elevated protein turnover and anorexia to cachexia in patients with hepatocellular carcinoma. Cancer Res. 1990 Feb 15;50(4):1226–1230. [PubMed]
  • Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 1987 Aug 14;50(4):555–563. [PubMed]
  • Pain VM, Randall DP, Garlick PJ. Protein synthesis in liver and skeletal muscle of mice bearing an ascites tumor. Cancer Res. 1984 Mar;44(3):1054–1057. [PubMed]
  • Platanias LC, Vogelzang NJ. Interleukin-1: biology, pathophysiology, and clinical prospects. Am J Med. 1990 Nov;89(5):621–629. [PubMed]
  • Pisters PW, Brennan MF. Amino acid metabolism in human cancer cachexia. Annu Rev Nutr. 1990;10:107–132. [PubMed]
  • Rivier C, Vale W, Brown M. In the rat, interleukin-1 alpha and -beta stimulate adrenocorticotropin and catecholamine release. Endocrinology. 1989 Dec;125(6):3096–3102. [PubMed]
  • Rodemann HP, Goldberg AL. Arachidonic acid, prostaglandin E2 and F2 alpha influence rates of protein turnover in skeletal and cardiac muscle. J Biol Chem. 1982 Feb 25;257(4):1632–1638. [PubMed]
  • Rodemann HP, Waxman L, Goldberg AL. The stimulation of protein degradation in muscle by Ca2+ is mediated by prostaglandin E2 and does not require the calcium-activated protease. J Biol Chem. 1982 Aug 10;257(15):8716–8723. [PubMed]
  • Saarinen UM, Koskelo EK, Teppo AM, Siimes MA. Tumor necrosis factor in children with malignancies. Cancer Res. 1990 Feb 1;50(3):592–595. [PubMed]
  • Sabatini M, Boyce B, Aufdemorte T, Bonewald L, Mundy GR. Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5235–5239. [PubMed]
  • Sabatini M, Yates AJ, Garrett IR, Chavez J, Dunn JF, Bonewald L, Mundy GR. Increased production of tumor necrosis factor by normal immune cells in a model of the humoral hypercalcemia of malignancy. Lab Invest. 1990 Nov;63(5):676–682. [PubMed]
  • Scuderi P, Sterling KE, Lam KS, Finley PR, Ryan KJ, Ray CG, Petersen E, Slymen DJ, Salmon SE. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet. 1986 Dec 13;2(8520):1364–1365. [PubMed]
  • Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, et al. Tumour necrosis factor in man: clinical and biological observations. Br J Cancer. 1987 Dec;56(6):803–808. [PMC free article] [PubMed]
  • Shapot VS. On the multiform relationships between the tumor and the host. Adv Cancer Res. 1979;30:89–150. [PubMed]
  • Sharp BM, Matta SG, Peterson PK, Newton R, Chao C, Mcallen K. Tumor necrosis factor-alpha is a potent ACTH secretagogue: comparison to interleukin-1 beta. Endocrinology. 1989 Jun;124(6):3131–3133. [PubMed]
  • Sheppard BC, Venzon D, Fraker DL, Langstein HN, Jensen JC, Norton JA. Prolonged survival of tumor-bearing rats with repetitive low-dose recombinant tumor necrosis factor. Cancer Res. 1990 Jul 1;50(13):3928–3933. [PubMed]
  • Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E, 3rd, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988 Feb;6(2):344–350. [PubMed]
  • Sherry BA, Gelin J, Fong Y, Marano M, Wei H, Cerami A, Lowry SF, Lundholm KG, Moldawer LL. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J. 1989 Jun;3(8):1956–1962. [PubMed]
  • Socher SH, Friedman A, Martinez D. Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice. J Exp Med. 1988 Jun 1;167(6):1957–1962. [PMC free article] [PubMed]
  • Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst. 1988 Jun 15;80(8):595–598. [PubMed]
  • Starnes HF, Jr, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W, Oettgen HF, Brennan MF. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest. 1988 Oct;82(4):1321–1325. [PMC free article] [PubMed]
  • Stovroff MC, Fraker DL, Norton JA. Cachectin activity in the serum of cachectic, tumor-bearing rats. Arch Surg. 1989 Jan;124(1):94–99. [PubMed]
  • Strelkov AB, Fields AL, Baracos VE. Effects of systemic inhibition of prostaglandin production on protein metabolism in tumor-bearing rats. Am J Physiol. 1989 Aug;257(2 Pt 1):C261–C269. [PubMed]
  • Svaninger G, Drott C, Lundholm K. Role of insulin in development of cancer cachexia in nongrowing sarcoma-bearing mice: special reference to muscle wasting. J Natl Cancer Inst. 1987 May;78(5):943–950. [PubMed]
  • Svaninger G, Gelin J, Lundholm K. Tumor-host wasting not explained by adrenal hyperfunction in tumor-bearing animals. J Natl Cancer Inst. 1987 Nov;79(5):1135–1141. [PubMed]
  • Svaninger G, Isaksson O, Lundholm K. Growth hormone and experimental cancer cachexia. J Natl Cancer Inst. 1987 Dec;79(6):1359–1365. [PubMed]
  • Tanaka Y, Tanaka T, Ishitsuka H. Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants. Cancer Res. 1989 Nov 1;49(21):5935–5939. [PubMed]
  • Tashjian AH, Jr, Voelkel EF, Lazzaro M, Goad D, Bosma T, Levine L. Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology. 1987 May;120(5):2029–2036. [PubMed]
  • Tayek JA, Istfan NW, Jones CT, Hamawy KJ, Bistrian BR, Blackburn GL. Influence of the Walker 256 carcinosarcoma on muscle, tumor, and whole-body protein synthesis and growth rate in the cancer-bearing rat. Cancer Res. 1986 Nov;46(11):5649–5654. [PubMed]
  • Tayek JA, Blackburn GL, Bistrian BR. Alterations in whole body, muscle, liver, and tumor tissue protein synthesis and degradation in Novikoff hepatoma and Yoshida sarcoma tumor growth studied in vivo. Cancer Res. 1988 Mar 15;48(6):1554–1558. [PubMed]
  • Tessitore L, Bonelli G, Baccino FM. Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia. Biochem J. 1987 Jan 1;241(1):153–159. [PubMed]
  • Tessitore L, Matera L, Bonelli G, Baccino FM, Dianzani MU. Aliphatic aldehydes inhibit the proliferative response of human peripheral blood lymphocytes to phytohemagglutinin and alloantigens. Chem Biol Interact. 1987;62(3):217–226. [PubMed]
  • Tessitore L, Bonelli G, Cecchini G, Amenta JS, Baccino FM. Regulation of protein turnover versus growth state: ascites hepatoma as a model for studies both in the animal and in vitro. Arch Biochem Biophys. 1987 Jun;255(2):372–384. [PubMed]
  • Theologides A. Pathogenesis of cachexia in cancer. A review and a hypothesis. Cancer. 1972 Feb;29(2):484–488. [PubMed]
  • Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran RS, Cerami A, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988 Mar 1;167(3):1211–1227. [PMC free article] [PubMed]
  • Trevisani A, Ferretti E, Capuzzo A, Tomasi V. Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumour growth by non-steroidal anti-inflammatory drugs. Br J Cancer. 1980 Mar;41(3):341–347. [PMC free article] [PubMed]
  • van Gool J, Boers W, Sala M, Ladiges NC. Glucocorticoids and catecholamines as mediators of acute-phase proteins, especially rat alpha-macrofoetoprotein. Biochem J. 1984 May 15;220(1):125–132. [PubMed]
  • Waage A, Espevik T, Lamvik J. Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol. 1986 Dec;24(6):739–743. [PubMed]
  • Waterlow JC. Protein turnover with special reference to man. Q J Exp Physiol. 1984 Jul;69(3):409–438. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK